More than 50 listed companies are set to declare their Q4FY25 earnings on 26 May 2025, keeping the focus squarely on stock-specific action. Key companies scheduled to report include Aurobindo Pharma, FirstCry, Gillette India, KEC International, and Sumitomo Chemical India (Sumichem).
Q4 earning results today: What to expect from key companies
Aurobindo Pharma is expected to report a year-on-year revenue growth of nearly 9% to ₹8,266 crore, with EBITDA seen rising to ₹1,819 crore. However, net profit is likely to remain nearly flat at ₹1,022 crore, compared to ₹1,030 crore last year. EBITDA margins are expected to remain stable at 22%.
FirstCry, on a quarter-on-quarter basis, is anticipated to post a sharp decline in profitability. Revenue is estimated to fall to ₹1,913 crore from ₹2,172 crore, while EBITDA is expected to shrink to ₹20 crore from ₹152 crore. Net loss is projected to widen to ₹95 crore from ₹8 crore.
Gillette India may post strong growth, with revenue seen at ₹729 crore versus ₹680 crore a year ago. EBITDA is expected to rise to ₹182 crore, and net profit to ₹123 crore from ₹99 crore, indicating continued margin improvement.
KEC International is expected to report healthy YoY growth with revenue seen at ₹6,986 crore (up from ₹6,164 crore), EBITDA at ₹557 crore, and net profit at ₹262 crore, versus ₹151 crore in the same quarter last year.
Sumitomo Chemical India (Sumichem) is also expected to deliver improved performance, with revenue likely at ₹722 crore and EBITDA at ₹141 crore, implying margin expansion to 19.55% from 15.02%.
Other companies scheduled to announce results include ACE, AUROPHARMA, AWFIS, BALAMINES, BAYERCROP, BLUEDART, FIRSTCRY, GILLETTE, GRAUWEIL, INFIBEAM, JINDRILL, KEC, LUMAXIND, MAHSEAMLES, NAZARA, OLECTRA, PTC, RATEGAIN, SAKSOFT, SHILPAMED, STYLAMIND, SUMICHEM, VENUSPIPES, and WINDMACHIN, among others.
Investors will closely track earnings trends, margin commentary, and management outlooks amid ongoing market volatility.